PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 2, aprile 2017

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Aflibercept
• Aluminium potassium sulfate hydrate/tannic acid
• Aripiprazole
• Canagliflozin
• Chlorhexidine gluconate
• Codeine
• Dienogest/ethinylestradiol containing products
• Direct-acting antivirals
• Fluoroquinolones
• Furosemide
• Hydroxyzine
• Hyoscine butylbromide
• Hypnotics/sedatives, anxiolytics and antiepileptics with drug dependence or withdrawal symptoms
• Idelalisib
• Iodine-containing contrast agents
• Itraconazole
• Lamotrigine
• Lithium carbonate
• Low-molecular-weight heparins
• Menthol containing OTC topical pain relievers
• Olanzapine
• SGLT2 inhibitors
• Tramadol-containing products
• Vemurafenib
• Warfarin

SAFETY OF MEDICINE
• Andrographis paniculata
• Bevacizumab used with colorectal stents
• Bisphosphonates
• Certain anti-neoplastic, immunosuppressant or immunomodulatory medications
• Eluxadoline
• Rivaroxaban, dabigatran and apixaban
• Vemurafenib
• Zostavax® (live, attenuated varicella-zoster virus vaccine)

SIGNAL
• Idelalisib and Leukoencephalopathy
• Panic attacks with levothyroxine